IRON Disc Medicine, Inc.
Price Chart
Executive Summary
Disc Medicine reported Q1 2026 results with a net loss of $63.5M ($1.65/share), wider than the $34.1M loss in Q1 2025, driven by increased R&D and SG&A spending. The company completed enrollment in the Phase 3 APOLLO study for bitopertin (topline data expected Q4 2026) and maintains a strong cash position of $730M, funding operations into 2029. The wider loss and lack of revenue are consistent with a clinical-stage biotech, but the stock will move on pipeline catalysts, not the financials.
Actionable Insight
The stock will trade on pipeline milestones, not quarterly financials. Key catalysts: bitopertin APOLLO topline data (Q4 2026), DISC-0974 ASCO presentation (June 2026), and DISC-3405 data (Q4 2026). Monitor for FDA Type A meeting outcome in Q2 2026.
Key Facts
- Net loss of $63.5M for Q1 2026 vs $34.1M in Q1 2025
- Net loss per share of $1.65 vs $1.02 in Q1 2025
- Cash, cash equivalents, and marketable securities of $730.2M as of March 31, 2026
- Completed enrollment of Phase 3 APOLLO study for bitopertin in EPP; topline data expected Q4 2026
- Type A meeting with FDA scheduled for Q2 2026 to review bitopertin resubmission approach
- Updated Phase 2 data for DISC-0974 in MF anemia selected for oral presentation at ASCO in June 2026
- Phase 2 study of DISC-3405 in PV and Phase 1b study in SCD progressing; data expected Q4 2026
Financial Impact
Net loss widened by $29.4M YoY to $63.5M; cash burn of ~$61M in Q1 2026
Risk Factors
- Bitopertin received a Complete Response Letter (CRL) from FDA in Feb 2026; approval path uncertain
- Widening net loss and increasing cash burn rate
- Clinical-stage biotech with no approved products or revenue
- Dilution risk from potential future equity offerings
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-205187 |
| Document: iron-20260505.htm | 0001193125-26-205187 |
| Document: 0001193125-26-205187-index-headers.html | 0001193125-26-205187 |
| Document: 0001193125-26-205187-index.html | 0001193125-26-205187 |
| Document: 0001193125-26-205187.txt | 0001193125-26-205187 |
| 8-K Data (Synthetic) | 0001193125-26-205187 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
Press Release
| $66.99 awaiting T+5 | awaiting T+5 | — | $68.34 (+2.02%) |
|
Jun 1, 2026
8d ago
|
Press Release
| $71.97 $67.00 | ▼ −6.91% | ▼ −4.16% | $68.34 (−5.04%) |
|
May 5, 2026
5w ago
|
8-K
| $67.59 $69.23 | ▲ +2.43% | ▲ +0.44% | $68.34 (+1.11%) |
|
May 5, 2026
5w ago
|
Press Release
| $67.59 $69.23 | ▲ +2.43% | ▲ +0.44% | $68.34 (+1.11%) |
|
Apr 13, 2026
8w ago
|
Insider Cluster
| $68.46 $71.41 | ▼ −4.31% | ▼ −1.01% | $68.34 (+0.18%) |
|
Feb 26, 2026
14w ago
|
8-K
| $67.91 $60.34 | ▲ +11.15% | ▲ +10.02% | $68.34 (−0.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access